Ajila, V., Shetty, H., Babu, S., Shetty, V., & Hegde, S. (2015). Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. Journal of Sexually Transmitted Diseases, 2015, 1–5. https://doi.org/10.1155/2015/791024
Barrett, D. M., Grupp, S. A., & June, C. H. (2015). Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street. The Journal of Immunology, 195(3), 755–761. https://doi.org/10.4049/jimmunol.1500751
de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., & Plummer, M. (2012). Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology, 13(6), 607–615. https://doi.org/10.1016/S1470-2045(12)70137-7
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. mAbs, 7(1), 9–14. https://doi.org/10.4161/19420862.2015.989042
Gill, S., & June, C. H. (2015). Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews, 263(1), 68–89. https://doi.org/10.1111/imr.12243
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L., & June, C. H. (2013). Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 368(16), 1509–1518. https://doi.org/10.1056/NEJMoa1215134
Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. Cell, 100(1), 57–70. https://doi.org/10.1016/S0092-8674(00)81683-9
Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., … Urba, W. J. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363(8), 711–723. https://doi.org/10.1056/NEJMoa1003466
Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2015). DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer, 16(1), 35–42. https://doi.org/10.1038/nrc.2015.4
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 14(9), 642–662. https://doi.org/10.1038/nrd4663
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016). Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine, 22(1), 26–36. https://doi.org/10.1038/nm.4015
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903–907. https://doi.org/10.1038/nature06309
Larson, C., Oronsky, B., Scicinski, J., Fanger, G. R., Stirn, M., Oronsky, A., & Reid, T. R. (2015). Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget, 6(24). https://doi.org/10.18632/oncotarget.5116
Lazebnik, Y. (2010). What are the hallmarks of cancer? Nature Reviews Cancer, 10(4), 232–233. https://doi.org/10.1038/nrc2827
Lingyun Geng. (2015). Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. International Journal of Clinical and Experimental Medicine, 8(9). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/
Matsuoka, M., & Jeang, K.-T. (2011). Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene, 30(12), 1379–1389. https://doi.org/10.1038/onc.2010.537
Morris, E. C., & Stauss, H. J. (2016). Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood, 127(26), 3305–3311. https://doi.org/10.1182/blood-2015-11-629071
Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265–277. https://doi.org/10.1038/nrc3258
Pierangeli, A., Antonelli, G., & Gentile, G. (2015). Immunodeficiency-associated viral oncogenesis. Clinical Microbiology and Infection, 21(11), 975–983. https://doi.org/10.1016/j.cmi.2015.07.009
Reichert, J. M. (2012). Marketed therapeutic antibodies compendium. mAbs, 4(3), 413–415. https://doi.org/10.4161/mabs.19931
Reichert, J. M. (2016). Antibodies to watch in 2016. mAbs, 8(2), 197–204. https://doi.org/10.1080/19420862.2015.1125583
Reichert, J. M. (2017). Antibodies to watch in 2017. mAbs, 9(2), 167–181. https://doi.org/10.1080/19420862.2016.1269580
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology, 12(4), 269–281. https://doi.org/10.1038/nri3191
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M., Lee, C.-C. R., Levy, C. L., Li, Y. F., El-Gamil, M., Schwarz, S. L., … Rosenberg, S. A. (2011). Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology, 29(7), 917–924. https://doi.org/10.1200/JCO.2010.32.2537
Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. (2011). Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331(6024), 1565–1570. http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents
Roos, W. P., Thomas, A. D., & Kaina, B. (2015). DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer, 16(1), 20–33. https://doi.org/10.1038/nrc.2015.2
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012). Oncolytic virotherapy. Nature Biotechnology, 30(7), 658–670. https://doi.org/10.1038/nbt.2287
Schinzari, V., Barnaba, V., & Piconese, S. (2015). Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection, 21(11), 969–974. https://doi.org/10.1016/j.cmi.2015.06.026
Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74. https://doi.org/10.1126/science.aaa4971
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001). IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410(6832), 1107–1111. https://doi.org/10.1038/35074122
Spurgeon, M. E., & Lambert, P. F. (2013). Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology, 435(1), 118–130. https://doi.org/10.1016/j.virol.2012.09.029
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., … Sznol, M. (2012). Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine, 366(26), 2443–2454. https://doi.org/10.1056/NEJMoa1200690
Varghese, S., & Rabkin, S. D. (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy, 9(12), 967–978. https://doi.org/10.1038/sj.cgt.7700537
Weinberg, R. A. (2014). The biology of cancer (2nd ed). Garland Science.
Weiss, R. A., & Vogt, P. K. (2011). 100 years of Rous sarcoma virus. The Journal of Experimental Medicine, 208(12), 2351–2355. https://doi.org/10.1084/jem.20112160
Wendzicki, J. A., Moore, P. S., & Chang, Y. (2015). Large T and small T antigens of Merkel cell polyomavirus. Current Opinion in Virology, 11, 38–43. https://doi.org/10.1016/j.coviro.2015.01.009
zur Hausen, H. (2009). Papillomaviruses in the causation of human cancers — a brief historical account. Virology, 384(2), 260–265. https://doi.org/10.1016/j.virol.2008.11.046